GFAP positivity in neurons following traumatic brain injuries

Johann Zwirner¹,²,³ • Julia Lier⁴ • Heike Franke⁵ • Niels Hammer⁶,⁷,⁸ • Jakob Matschke⁹ • Florian Trautz³ • Rexon Tse¹⁰ • Benjamin Ondruschka²

Received: 10 January 2021 / Accepted: 10 March 2021 / Published online: 11 June 2021
© The Author(s) 2021

Abstract
Glial fibrillary acidic protein (GFAP) is a well-established astrocytic biomarker for the diagnosis, monitoring and outcome prediction of traumatic brain injury (TBI). Few studies stated an accumulation of neuronal GFAP that was observed in various brain pathologies, including traumatic brain injuries. As the neuronal immunopositivity for GFAP in Alzheimer patients was shown to cross-react with non-GFAP epitopes, the neuronal immunopositivity for GFAP in TBI patients should be challenged. In this study, cerebral and cerebellar tissues of 52 TBI fatalities and 17 controls were screened for immunopositivity for GFAP by means of immunohistochemistry and immunofluorescence. The results revealed that neuronal immunopositivity for GFAP is most likely a staining artefact as negative controls also revealed neuronal GFAP staining. However, the phenomenon was twice as frequent for TBI fatalities compared to non-TBI control cases (12 vs. 6%). Neuronal GFAP staining was observed in the pericontusional zone and the ipsilateral hippocampus, but was absent in the contralateral cortex of TBI cases. Immunopositivity for GFAP was significantly correlated with the survival time ($r = 0.306$, $P = 0.015$), but no correlations were found with age at death, sex nor the post-mortem interval in TBI fatalities. This study provides evidence that the TBI-associated neuronal immunopositivity for GFAP is indeed a staining artefact. However, an absence post-traumatic neuronal GFAP cannot readily be assumed. Regardless of the particular mechanism, this study revealed that the artefact/potential neuronal immunopositivity for GFAP is a global, rather than a regional brain phenomenon and might be useful for minimum TBI survival time determinations, if certain exclusion criteria are strictly respected.

Keywords Glial fibrillary acidic protein • Immunofluorescence • Immunohistochemistry • Neuron • Traumatic brain injury

Introduction
Traumatic brain injury (TBI) is defined as a chronic disease process [1] that contributes considerably to the global burden of injury [2]. Traumatic impact to the head causes glial, neuronal and axonal injuries followed by neuroinflammation and an activation of microglia [3–5]. The resulting brain damage and the subsequent recovery are indirectly reflected by an increase or decrease in intracellular proteins within brain tissue or other organic compounds within particular body fluids, which are, therefore, deemed as cerebral biomarkers [6]. Some common examples of TBI-related...
biodemokar are neuron-specific enolase, brain-derived neurotrophic factor, tau protein, neurofilament, myelin basic protein, S100 calcium-binding protein B (S100B), interleukin 6 (IL-6) and glial fibrillary acidic protein (GFAP) [3, 5, 7–11].

In a post-mortem setting, TBI-related biomarkers can be investigated within the brain to explore the pathophysiological characteristics of TBI. Alternatively, these biomarkers may be utilized to establish new forensic methods for estimating survival time and time since death. However, only few forensic studies have systematically investigated TBI-related biomarkers within human brain tissue [5, 12–16], to date. As a result, little is known about the post-traumatic pathophysiology of these markers at a cellular level. Surprisingly, previous studies from our group observed S100B within neurons following TBI after a minimum survival time of 2 h, a marker which is usually known to be specific for glial cells (astrocytes, oligodendrocytes) [12, 13]. It is unclear whether neurons synthesize glia-specific proteins following the traumatic brain injury or whether these proteins enter the neuron via an active or passive transport pre-mortem or post-mortem. Moreover, the aforementioned observations of S100B raise the question whether other TBI-related biomarkers that are normally not known as neuron specific or even neuronally expressed can also be detected in neurons following the traumatic brain injury.

GFAP is the major protein component of glial intermediate filaments, which substantially increases within astrocytes in response to a traumatic brain injury [17]. Clinically, increased blood levels of GFAP were shown to be a well-suited biomarker to discriminate TBIs from controls [18, 19]. Detection of GFAP in post-mortem serum [9, 10] and cerebrospinal fluid [10] samples is also a suitable method to discriminate between lethal TBIs and controls. Both clinically and forensically, the potential to discriminate TBIs from controls was further improved when GFAP was used in combination with other biomarkers such as ubiquitin C-terminal hydrolase-L1 [20] or IL-6 [21].

GFAP-positive staining of human neurons following traumatic brain injury was previously observed in the CA2, CA3 and CA4 regions of the hippocampus in subacute and delayed deaths [22]. Furthermore, an increase in GFAP expression in rodent hippocampal neurons was shown after TBI using single-cell RNA sequencing [23]. However, it remains unclear to date whether the neuronal positivity for GFAP is an exclusive observation for the hippocampus or also affects other brain regions. In light of previous observations of cross-reactions between GFAP antibodies and epitopes of neurofilament-L in Alzheimer’s disease (AD) patients [24], this given study will particularly focus on the possibility that neuronal GFAP is a processing artefact, rather than a reactive process following brain injuries.

Material/methods

Retrieval of human brain tissue samples

This study re-evaluated digitalized photographs of brain tissue samples taken from 50 TBI fatalities and 16 controls collected for our study on astrocytic GFAP expression following traumatic brain injuries (for individual case details see Trautz et al. [5]). In brief, human brain samples were retrieved during forensic autopsies; afterwards, they were submerged in neutral buffered 4% formaldehyde, which was changed once after 24 h. The duration of fixation was up to 3 weeks before embedding in paraffin. The control samples were collected from individuals who died of sudden natural cardiovascular causes of death with absence of acute or former injuries of the central nervous system. To investigate a potential region dependency of immunopositivity for GFAP in neurons within the brain in TBI fatalities, samples from the following four brain sites were evaluated: (i) the cerebral area (cortex and adjacent white matter) next to the either microscopically (haemorrhages with abundant necrotic tissue) or macroscopically verified contusions, (ii) a cerebral region (cortex and adjacent white matter) opposite to the contusion called the contralateral cortex (CLC), which was microscopically and macroscopically free of contracoup haemorrhages, (iii) the CA4 region of the hippocampus (HC) and (iv) the cerebellum (CB). Hippocampal and cerebellar samples were taken from regions ipsilateral to the cerebral contusion as also performed previously [5, 12, 15].

Using semiquantitative analyses, the contusions were located in the prefrontal, temporoparietal and occipital regions of the brain in 22, 23 and 5 TBI fatalities, respectively. For controls, samples were retrieved from the following brain regions, which varied from TBI fatalities as no impact zone was present: (i) the frontal cortex and adjacent white matter (FC), (ii) the ipsilateral CA4 region of the HC and (iii) the ipsilateral CB.

In line with previous studies [5, 12], the TBI cases were further categorized into the following three groups according to their survival time following the traumatic event: an acute group (survival time < 2 h), a subacute group (survival time 2–72 h) and a delayed group (survival time > 72 h). The Ethics Committee of the University of Leipzig, Germany approved the study (local number 117–12-23,012,012).

Histology, immunohistochemistry and assessment

The brain samples allocated to the subgroups and their respective sample characteristics are depicted in Table 1. Routine H&E stains were available to assess the overall
Table 1 The case characteristics for the 50 TBI fatalities and 16 controls (sudden cardiovascular fatalities) that were included in the semiquantitative analysis of GFAP positivity in neurons in this study. Note that no survival time was assumed for control cases due to the immediate death resulting from the fatal cardiovascular event. *H hours, min minutes*

| Group                        | Sex | Age            | Survival time | PMI          |
|------------------------------|-----|----------------|---------------|--------------|
|                              |     | Range/Median   | Range/Median  | Range/Median |
| TBI fatalities                |     |                |               |              |
| Acute death                  | 7   | 17             | 18–75 years   | 44 years     |
| Subacute death               | 4   | 11             | 23–85 years   | 62 years     |
| Delayed death                | 2   | 9              | 26–81 years   | 57 years     |
| Control group (sudden cardiovascular fatalities) | 7   | 9              | 27–91 years   | 64 years     |

morphology and potential trauma-related or inflammatory changes. The immunolabelled slices were stained with a polyclonal rabbit GFAP antibody (catalogue number Z0334; Agilent Dako, Santa Clara, USA), dilution 1:4000, performed with a fully automated immunostainer (Benchmark XT; Roche, Basel, Switzerland) using DAB as standard chromogen. For each brain region per case, a set of ten coherent “high-power field” (HPF) images was assessed, resulting in a standardized investigation area of 2.37 mm² per region [25]. The commercially available object counting application SIGMA (open source, developed by Karen Grigoryan) was used to evaluate the slides in all ten digital HPF images at ×200. Only cells with a distinct cellular immunostaining which were identified as neuronal in origin were counted to ensure a repeatability of the results. Here, nucleus morphology, nucleolus location and cell boarders were used to differentiate neurons from non-neuronal cells as established morphological criteria. After immunopositivity for GFAP was noted in the neurons, the consecutive slides were stained analogously per immunolabelling and counterstained with haematoxylin.

The overall staining intensity of the section was rated according to the scoring system of Remmel and Stegner [26] to relate the observed results of this study to the staining quality of the brain tissue. The scoring system implemented the following grades: (0) absence of noticeable staining, (1) slight staining with the marker being predominantly concentrated on cell bodies, (2) moderate staining with incidental spots that are more intensively coloured and some blunt processes and (3) strong staining with predominantly condensed central granulations and widespread processes. The final grade was generated by the arithmetic mean of the ten sections available per region.

Immunofluorescence

To confirm or reject the immunohistochemical observations, an additional staining technique was performed employing immunofluorescence labelling on brain tissue of two additional TBI fatalities and one control case, which were not included in the dataset of Trautz et al. [5]. Both TBI cases were male, and were 18 and 32 years old at death. Both cases had a survival time of less than 10 min and post-mortem intervals of under 48 h. The control case was a 50-year-old male who died of an acute cardiac arrest. The procedure was performed twice using primary and secondary antibodies of different batches and manufacturers to exclude that the observations were attributed to a specific batch (or manufacturer) of antibodies (Table 2). Also, negative controls were made concomitantly to test for unspecific binding. Whereas the Agilent Dako GFAP antibody “reacts strongly with human GFAP”, the BD Pharmingen anti-GFAP cocktail “specifically detects GFAP and does not cross-react with other intermediate filaments” according to the details provided by both manufacturers. Since antibody “cocktails” are composed of monoclonal antibodies combining several targets, one could describe them as oligoclonal antibodies, combining the specificity of monoclonal and the sensitivity of polyclonal antibodies. NeuN was used as a typical and specific neuronal marker of human brain tissue [27].

The tissue was cut into 12-μm-thick serial sections. Antigen retrieval was achieved using microwave pre-treatment in citrate buffer (pH=6.0, 98 °C, 2×20 min). Tissues were washed and then blocked with 1% bovine serum albumin (BSA; A7906, Sigma-Aldrich, St. Louis, USA) in PBS-Triton (0.03%, PBS-T) to prevent further non-specific binding. Then, sections were incubated with the primary antibodies overnight in an adequate dilution in 0.5% BSA in PBS-T at 4 °C (Table 2). For the negative controls, the primary antibody was omitted and the section was incubated in 0.5% BSA in PBS-T overnight. After rinsing with PBS-T, the Alexa Fluor 488 and Alexa Fluor 568-conjugated secondary antibodies were applied and the slices were incubated for 60 min at room temperature at a dilution of 1:200. Counterstaining with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, dilution 1:50,000; Invitrogen, Waltham, MA, USA) was done to detect cell nuclei. Slices were then washed and cover slipped. Images were taken.
using an Olympus BX40 fluorescent microscope (Olympus Deutschland, Hamburg, Germany). Due to the young age of the tested individuals, no lipofuscin quenching was performed to prevent a decrease of staining intensity.

Statistical analyses

Data analysis was conducted using Prism version 8 (GraphPad Software, La Jolla, CA, USA) and Microsoft Excel version 16.16 (Microsoft Corporation, Redmond, WA, USA). The Shapiro–Wilk test was used to test the Gaussian distribution of the data. Pearson’s $r$ and Spearman’s $\varrho$ were reported for parametric and non-parametric data, respectively. The occurrence of immunopositivity for GFAP in neurons of any brain region per cadaver was correlated with age at death, sex, survival time and PMI. The total number of immunopositivity for GFAP in neurons was correlated with the total number of GFAP-positive astrocytes of the respective brain region (metadata in Trautz et al. [5]) and the staining score mentioned above. $P$-values of 0.05 or less were considered to be statistically significant.

Results

**Immunopositivity for GFAP in neurons was detected in TBI cases and controls and this correlated with the survival times in TBI cases**

Immunopositivity for GFAP in neurons in any of the investigated brain regions was detected in 6 out of 50 TBI cases (12%), as well as 1 (44-year-old male who died of an acute coronary insufficiency) out of 16 controls (6%). A significant and moderately positive correlation was observed between the survival time and the occurrence of immunopositivity for GFAP in neurons in any of the four investigated sub-regions from the TBI cases ($r = 0.306, P = 0.015$). The occurrence of immunopositivity for GFAP in neurons in any of the sub-regions did not correlate with age at death ($r = -0.016, P = 0.451$), sex ($r = -0.013, P = 0.459$) and PMI ($r = 0.011, P = 0.467$) on a statistically significant level for TBI cases. Age, sex and PMI correlations were not performed for control cases due to the limited sample size.

**Immunopositivity for GFAP in neurons in TBI cases was observed in the pericontusional zone and the ipsilateral hippocampus, but not the contralateral cortex**

Immunopositivity for GFAP in neurons was observed in the PCZ and HC of 13 and 17% of the subacute TBI fatalities (Fig. 1). Similarly, immunopositivity for GFAP in neurons was found in 17 and 18% of the HC and PCZ in delayed TBI fatalities, respectively (Fig. 1). The CB contained immunopositivity for GFAP in neurons in 14% of subacute TBI fatalities (Fig. 1). None of the acute TBI cases or CLC regions of subacute and delayed TBI fatalities revealed any immunopositivity for GFAP in neurons (Fig. 1). Control samples showed immunopositivity for GFAP only in Purkinje neurons in 6% of cerebellar samples (Fig. 1). The two TBI samples that presented immunopositivity for GFAP in Purkinje neurons had a contusion in the prefrontal cortex area. Immunopositivity for GFAP in neurons was found in the HC following both temporal

| Dilution | Host | Company (headquarter, state, country) | Catalogue number | Experiment number |
|----------|------|--------------------------------------|-----------------|------------------|
| 1:400    | Rabbit | Agilent Dako (Santa Clara, CA, USA) | Z0334           | 1                |
| 1:400    | Mouse | BD Pharmingen Inc (San Diego, CA, USA) | 556,330         | 2                |
| 1:500    | Mouse | Millipore Sigma (Burlington MA, USA) | MAB377          | 1                |
| 1:500    | Rabbit | Millipore Sigma (Burlington MA, USA) | ABN78           | 2                |
| 1:200    | Donkey | Invitrogen, Thermo Fisher, Scientific (Waltham, MA, USA) | A21206         | 1                |
| 1:200    | Donkey | Invitrogen, Thermo Fisher, Scientific (Waltham, MA, USA) | A21202         | 1                |
| 1:200    | Donkey | Invitrogen, Thermo Fisher, Scientific (Waltham, MA, USA) | A10042         | 2                |
| 1:200    | Donkey | Invitrogen, Thermo Fisher, Scientific (Waltham, MA, USA) | A10037         | 2                |
contusions \((n = 2)\) and a prefrontal cortical contusion \((n = 1)\). No immunopositivity for GFAP in neurons was detected in the frontal cortices or hippocampi of controls.

**The absolute number of GFAP-labelled neurons per sub-region is low**

The low absolute number of GFAP-labelled neurons correlated only weakly and insignificantly with the number of GFAP-positive astrocytes of the respective HPF \((r = 0.247, P = 0.244)\). Also, the adapted Remmele and Stegner staining score did not influence the absolute number of GFAP-labelled neurons significantly \((r = 0.086, P = 0.410)\). Figure 2 shows typical GFAP-positive astrocytes, as well as immunopositivity for GFAP in representative neuronal cells in the anti-GFAP immunolabellings that were evaluated in this study.

**Immunofluorescence stains reveal non-specific binding of the secondary antibody**

The double immunofluorescence stains with primary anti-GFAP and anti-NeuN antibodies revealed GFAP-positive staining within vital (DAPI-positive) neuronal cell bodies, which are also positively labelled with NeuN (Fig. 3a). However, a comparable, more peripheral and granular reaction of the secondary antibody was observed in the negative control (Fig. 3b). These positive stainings were present even when another antibody batch was used for both the primary and secondary antibodies, respectively. Furthermore, the GFAP-positive stainings were detected for both of the secondary antibodies used in this study (Fig. 4). However, comparable GFAP-positive stainings were also present in the 488-channel for the negative control.

**Discussion**

Traumatic brain injuries were shown to impact cell typespecific genes and additionally alter the genomic co-expression across cell types [23]. With regard to GFAP, a TBI-related neuronal deposition was observed previously and was suspected to be induced by the traumatic event [22]. Additionally, the former study suggested that the distinct immunopositivity for GFAP could highlight a GFAP-related protein, rather than actual GFAP positivity [22]. Moreover, neuronal GFAP staining was observed in
AD patients [28], which further substantiates that neuronal GFAP might be related to neuron degeneration or damage, thereby corroborating the findings in TBI cases [22]. However, the immunopositivity for GFAP in AD patients was shown to be related to a cross-reactivity of the GFAP antibody with neurofilament-L [24]. This was attributed to a homology between amino acids of the GFAP+1 peptide and the tail domain of neurofilament-L [24]. Therefore, the current study not only performed a standard negative control, but also confirmed the findings applying another antibody batch and even an additional immunofluorescence stain. The results of this study suggest the neuronal immunopositivity for GFAP is a processing artefact, rather than an actual reactive neuronal occurrence of GFAP post-TBI. With respect to the previous findings of neuronal immunopositivity for GFAP and the fact that this given study cannot entirely prove the absence of neuronal GFAP, factors for and against a neuronal staining of GFAP will be discussed separately below.

Fig. 2 GFAP positivity in neurons is depicted in different regions of the brain. a Counterstaining was conducted with blueing reagent, which visualizes the neurons (black arrow). GFAP-positive astrocytes are depicted (red arrow). b In the cerebellar cortex, immunopositivity for GFAP is depicted for Purkinje neurons (black arrow) and Bergmann glial cells (red arrow). The granular layer contains abundant GFAP-negative granular cells (blue arrows). c The GFAP positivity in several neurons (black arrows) of the cerebral cortex is accompanied by GFAP-positive astrocytes (red arrows) and GFAP-negative neuronal cell bodies (blue arrows) in the anti-GFAP immunolabelling. Scale bars: 100 µm (a), 25 µm (b) and 100 µm (c).

Fig. 3 Immunofluorescence images of the cerebral cortex of a 32-year-old donor are depicted. a A neuron is stained with anti-NeuN (white arrow) immunolabelling. The anti-GFAP immunolabelling shows GFAP-positive astrocytes (red arrow), as well as GFAP-positive staining within the NeuN-positive neuron (NeuN is predominantly a nuclear marker). b The negative control for the anti-GFAP immunolabelling reveals a non-specific binding of the secondary antibody to the deposits (blue arrow) within a NeuN-positive neuron (white arrow). Scale bars 10 µm.
Indicators and explanations for an absence of neuronal GFAP

Even though remarkable evidence exists that supports the neuronal potential to synthesize GFAP mRNA [23, 28], it has to be considered that the GFAP immunoreaction might solely be an artefact and, therefore, not truly depict neuronal GFAP. Regarding the former, the strongest argument in this given study forms the observation of fluorescent neuronal staining in the negative control of the anti-GFAP stain. The immunopositivity of the anti-GFAP-negative control suggests a non-specific binding of the secondary antibody, which contradicts the observation of neuronal GFAP. Regarding this, Middeldorp and colleagues were able to show that a neuronal staining with different GFAP antibodies was caused by a cross-reaction with neurofilament-L (NF-L). This is most likely due to a homology of the GFAP peptide with several amino acids in the tail domain of NF-L [24]. Even though the antibodies used are described to have increased specificity in epitope binding, the exact epitope the antibody was binding to is unknown. Therefore, it is possible that the antibody cross-reacted with similar proteins, hence binding different epitopes than the intended GFAP ones [24]. Interestingly, in this given study, TBI cases were more likely to contain GFAP-positive neuronal deposits, similar to the increased findings in AD brains [28] and, therefore, could be a hint for the trauma-associated neuronal damage. Alternatively, it could be suspected that the observed neuronal staining reflects lipofuscin, as mentioned previously; in this study, no lipofuscin quenching was performed due to the young age of the tested individuals. A proteomics study was able to detect GFAP as a major lipofuscin protein in humans, but not in rats [29]. In addition, lipofuscin was described to have a yellow–brown or translucent appearance under visible light [30]. However, an age-related increase would be expected for lipofuscin [31], which was not observed for the neuronal GFAP staining in this study. Furthermore, the increase of GFAP-positive staining in cases with traumatic brain injury could reflect an increase in lipofuscin and, therefore, an accelerated neurodegeneration following a traumatic brain injury. The former correlation was already described in several studies before [32].

A third possible explanation is the probability of metabolic alterations, such as acidosis [33] of brain tissue after severe traumatic events. The authors hypothesize that this might alter epitopes of intraneuronal proteins, thereby increasing the likelihood of a non-specific antibody binding. However, the altered neuronal homeostasis and its respective impact on neuronal proteins might just lead to a non-specific binding of secondary antibodies, if the vital neuron was exposed to the metabolic change for at least 2 h.

Indicators and potential explanations for a neuronal accumulation of GFAP

GFAP is known to be a glia-specific biomarker [17, 34]. Being an intermediate filament, it is thought to contribute to cell stability [24]. Furthermore, recent studies determined...
GFAP plays an important role in myelination, synaptic plasticity, scar formation or the integrity of the blood–brain barrier [35–38]. Studies using a targeted deletion of the GFAP gene in embryonic stem cells creating GFAP knockout mice failed to distinguish a specific phenotype [38–40]. However, immunopositivity for GFAP in neurons was observed in pathologically altered human brain tissue, which was observed at the protein level [22, 28, 41], as well as at the RNA level [23]. Furthermore, patients suffering from AD presented out-of-frame splice forms of GFAP mRNA [28], which might result in impaired protein interaction [24]. A potential cell damage or stress might be visualized by the here observed satellitosis, which surrounded GFAP-positive labelled neurons. The neuronal origin of these immunopositive cells was proven by the double immunolabelling with the neuronal marker NeuN. The current study observed the potential immunopositivity for GFAP in few scattered neurons, rather than in all neurons of the investigated area. However, this may be due to GFAP being present in most but not all neuronal cell types, as shown with NeuN [42]. The authors hypothesize that the former might reflect an adaptation to a decreased energy supply following the traumatic event and provide an advantage to survive an acute stressful situation. The adaptation mechanism might be similar to the proposed temporary retro-differentiation of the neurons of AD patients to a GFAP-positive precursor, which differentiate into neurons after the stress survival [28].

GFAP is the major intermediate filament protein in the adult brain and characteristic for mature astrocytes. During development, GFAP is expressed by radial glia. These bipolar cells are located in the ventricular zone and have the ability to act as neural stem cells [43–45]. However, this expression only lasts during gestation. In contrast, neural precursor cells of the subventricular zone display an expression of GFAP [46, 47], which persists into adulthood [48]. With regard to TBI, immunopositivity for GFAP in neurons were detected in the CA2, CA3 and CA4 regions of the HC previously and were thought to be the result of brain swelling and brain stem haemorrhages [22]. The former study also used immunofluorescence to highlight GFAP-positive staining in neurons [22]. The results confirm the previous observation of hippocampal immunopositivity for GFAP in neurons following traumatic brain injuries [22]. Furthermore, immunopositivity for GFAP in neurons was also observed in the PCZ and the CB ipsilateral to the traumatic brain injury. Remarkably, immunopositivity for GFAP in neurons was absent in all the investigated CLCs, but was observed in the CB only in prefrontal contusions. Therefore, if the given study truly depicts intraneuronal GFAP, the data presented in this study supports that immunopositivity for GFAP in neurons occur in an area adjacent and ipsilateral to the contusion, except for some Purkinje neurons. This implies that Purkinje neurons might be more susceptible to show GFAP-positive staining in contrecoup injuries compared to cerebral neurons. However, this observation should be confirmed in a future study with a larger sample size, in order to determine its statistical significance. Contrary to the neuronal observations, the number of GFAP-positive astrocytes was shown to increase in the cerebral cortex contralateral to the contusion [5]. Only one of the 16 controls presented immunopositivity for GFAP in neurons, and this was located in the CB. Therefore, it can be hypothesized that either a small number of immunopositivity for GFAP in neurons may be expected in the CB in an atraumatic patient cohort or the person had an unknown history of a traumatic brain injury during their lifetime, or undiagnosed brain injury at death. Also, as all control cases died from sudden cardiovascular diseases, the occurrence of GFAP in neurons might be related to this disorder.

The results of this study revealed that neuronal immunopositivity for GFAP is influenced by the trauma survival time. Immunopositivity for GFAP in neurons was only observed in subacute and delayed TBIs, corroborating previous observations on immunopositivity for GFAP in hippocampal neurons [22]. This was explained by an induced expression of GFAP or a structurally related protein that is stained by the anti-GFAP immunolabelling, as well as a consequence of post-traumatic brain swelling [22]. Similarly, S100+ in neurons was mainly detected in subacute and delayed TBIs previously, with only few positive cases in acute deaths [12, 13]. Several studies and the GFAP expression pattern in certain neuronal stem cells provide evidence of the neuronal ability to express mRNA for GFAP [28, 46]. Recently, a study researching the effects of traumatic brain injury using scRNA sequencing showed an increase in neuronal GFAP expression following a traumatic event in rodents ([23] Supplemental Data). This given study reveals that supratentorial neuronal GFAP can be expected 2 h after the traumatic event, at the earliest. It has to be noted that the post-injury behaviour of the neuronal plasma membrane is not fully understood to date. It is also unclear whether GFAP with a molecular size of 50 kDa [49] can pass the damaged neuronal plasma membrane, as it is 40 kDa larger in size of the molecule that was shown to pass the disrupted membrane, previously [50]. GFAP concentrations in the cerebrospinal fluid and serum were shown to significantly increase immediately following the traumatic event [10]. However, in this study, no statistically significant changes with increasing survival times were observed [10].

Implications of stated results for forensic questions

With regard to forensic questions such as cause of death determination, time since death estimation or survival time estimation, the usability of the findings presented in this study is limited. The GFAP immunolabelling of neurons in patients suffering from AD [28] or tuberous sclerosis [41] highlights that immunopositivity for GFAP in neurons is not TBI-specific. At most, immunopositivity for GFAP in...
neurons indicates a pathological state of the brain, which does not allow for a distinct cause of death determination. The immunopositivity for GFAP in neurons lacks useful information for forensic time since death estimations as the PMI did not significantly correlate with the presence of immunopositivity for GFAP in neurons in this study. However, the presented findings may be useful for TBI survival time estimations in certain cases. If a GFAP immunostained neuron is present in the PCZ or the HC, the survival time after the traumatic brain injury was likely exceeding 2 h. However, it also needs to be mentioned that the “minimum survival time” determination based on supratentorial immunopositivity for GFAP in neurons can be biased, if the deceased suffered from neurodegenerative diseases. The absence of immunopositivity for GFAP in neurons lacks useful information on the survival time as an absence of neuronal immunopositivity for GFAP is the “expected” staining result and was found regardless of the survival time or the mechanism of death.

Limitations

Firstly, this study was limited in sample size, which affected the stated results. An increase of the case numbers could either lead to an increase of the correlation coefficient, which would strengthen the correlation or further decrease the P-value, which would just reassure us of the weak correlation [51, 52]. Hence, distinguishing between the mere statistical relation and the actual clinical value is necessary. Secondly, a potential degradation of GFAP has previously been reported when samples were stored for long periods [5]. However, in this study, the positive immunoreaction for GFAP in neurons did not correlate with the PMI on a statistically significant level, with the given sample size. Thirdly, single-cell immunopositivity for GFAP in neurons might have been missed during the here performed counting, which might have led to an underestimation of the stated immunopositivity for GFAP in neurons. Fourthly, immunopositivity for GFAP in neurons might not have been stained with the here applied methodology for an unknown reason. Thus, it is important to state that the absence of immunopositivity for GFAP in neurons in the here stated GFAP-negative brain samples does not imply to be the proof of any neuronal GFAP absence. Fifthly, samples were paraffin-embedded within 1–3 weeks after being formalin-fixed. This difference in formalin storage time might have impacted the semiquantitative evaluation of the given study. Future studies should use cryosectioning to evaluate whether the here observed immunopositivity for GFAP was related to the formalin storage. Furthermore, this study lacks a distinction of the particular GFAP isoforms [53–55]. A more detailed investigation would be needed to thoroughly discuss the appearance and meaning of possible GFAP-positive staining in neurons.

Conclusions

This study provides evidence that a TBI-associated neuronal positivity for GFAP is indeed a staining artefact; however, an absence of post-traumatic neuronal GFAP cannot be confirmed. Regardless of the particular mechanism, this study revealed that the artefact/potential neuronal immunopositivity for GFAP is a global, rather than a regional brain phenomenon and might be useful for determining a minimum TBI survival time, if certain exclusion criteria are strictly respected.

Acknowledgements The authors thank Ms Joanna Tomlinson for her efforts in proofreading the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Ethical approval All experiments were conducted in accordance with the general and human ethical principles of the University of Leipzig (no. 117–12-23012012).

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Masel BE, DeWitt DS (2010) Traumatic brain injury: a disease process, not an event. J Neurotrauma 27:1529–1540. https://doi.org/10.1089/neu.2010.1358
2. Injury GBDTDB, Spinal Cord Injury C (2019) Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:56–87. https://doi.org/10.1016/S1474-4422(18)30415-0
3. Zetterberg H, Blennow K (2016) Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol 12:563–574. https://doi.org/10.1038/nrneurol.2016.127
4. Lier J, Ondruschka B, Bechmann I, Dressler J (2020) Fast microglial activation after severe traumatic brain injuries. Int J Legal Med. https://doi.org/10.1007/s00414-020-02308-x
5. Trautz F, Franke H, Bohnert S et al (2019) Survival-time dependent increase in neuronal IL-6 and astrogial GFAP expression in fatally injured human brain tissue. Sci Rep 9:11771. https://doi.org/10.1038/s41598-019-48145-w
6. Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5:463–466. https://doi.org/10.1097/COH.0b013e32833ed177
7. Ondruschka B, Pohlers D, Sommer G et al (2013) S100B andNSE as useful postmortem biochemical markers of traumatic brain injury in autopsies cases. J Neurotrauma 30:1862–1871. https://doi.org/10.1089/neu.2013.2895
8. Ondruschka B, Schuch S, Pohlers D, Franke H, Dressler J (2018) Acute phase response after fatal traumatic brain injury. Int J Legal Med 132:531–539. https://doi.org/10.1007/s00414-017-1768-2
9. Ondruschka B, Woydt L, Bernhard M et al (2019) Post-mortem in situ stability of serum markers of cerebral damage and acute phase response. Int J Legal Med 133:871–881. https://doi.org/10.1007/s00414-018-1925-2
10. Ondruschka B, Sieber M, Kirsten H, Franke H, Dressler J (2018) Measurement of cerebral biomarkers proving traumatic brain injuries in post-mortem body fluids. J Neurotrauma 35:2044–2055. https://doi.org/10.1089/neu.2017.5441
11. Woydt L, Bernhard M, Kirsten H et al (2018) Intra-individual alterations of serum markers routinely used in forensic pathology depending on increasing post-mortem interval. Sci Rep 8:12811. https://doi.org/10.1038/s41598-018-31252-5
12. Krohn M, Dressler J, Bauer M, Schober K, Franke H, Ondruschka B (2015) Immunohistochemical investigation of S100 and NSE in cases of traumatic brain injury and its application for survival time determination. J Neurotrauma 32:430–440. https://doi.org/10.1089/neu.2014.3524
13. Li DR, Zhu BL, Ishikawa T, Zhao D, Michiue T, Maeda H (2006) Immunohistochemical detection of S-100 protein in the cerebral cortex with regard to the cause of death in forensic autopsy. Leg Med (Tokyo) 8:78–85. https://doi.org/10.1016/j.legalmed.2005.09.002
14. Dressler J, Hanisch U, Kuhlisch E, Geiger KD (2007) Neuronal and glial apoptosis in human traumatic brain injury. Int J Legal Med 121:365–375. https://doi.org/10.1007/s00414-006-0126-6
15. Staffa K, Ondruschka B, Franke H, Dressler J (2012) Cerebellar gene expression following human traumatic brain injury. J Neurotrauma 29:2716–2721. https://doi.org/10.1089/neu.2011.2246
16. Hausmann R, Riess R, Fiegluth A, Betz P (2000) Immunohistochemical investigations on the course of astroglial GFAP expression following human brain injury. Int J Legal Med 113:70–75. https://doi.org/10.1007/s00414-000-0711-0
17. Eng LF (1985) Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 8:203–214. https://doi.org/10.1016/s0165-5728(85)80063-1
18. Bogoslovsky T, Wilson D, Chen Y et al (2017) Increases of plasma levels of glial fibrillary acidic protein, tau, and amyloid beta up to 90 days after traumatic brain injury. J Neurotrauma 34:66–73. https://doi.org/10.1089/neu.2015.4333
19. Papa L, Brophy GM, Welch RD et al (2016) Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurology 73:551–560. https://doi.org/10.1001/jamaneurol.2016.0039
20. Diaz-Arrastia R, Wang KK, Papa L et al (2014) Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 31:19–25. https://doi.org/10.1089/neu.2013.3040
21. Zwirner J, Bohnert S, Franke H et al [in submission] IL-6 and GFAP as a compelling biomarker combination to detect lethal acute traumatic brain injuries in cerebrospinal fluid
22. Li DR, Ishikawa T, Zhao D et al (2009) Histopathological changes of the hippocampus neurons in brain injury. Histol Histopathol 24:1113–1120. https://doi.org/10.14670/HH-24.1113
23. Arneson D, Zhang G, Ying Z et al (2018) Single cell molecular alterations reveal target cells and pathways of concussive brain injury. Nat Commun 9:3894. https://doi.org/10.1038/s41467-018-06222-0
24. Middeldorp J, van den Berge SA, Aronica E, Speijer D, Hol EM (2009) Specific human astrocyte subtype revealed by affinity purified GFAP antibody; unpurified serum cross-reacts with neurofilament-L in Alzheimer. PLoS ONE 4:e7663. https://doi.org/10.1371/journal.pone.0007663
25. Trautz F, Dressler J, Stassart R, Muller W, Ondruschka B (2018) Proposals for best-quality immunohistochemical staining of paraffin-embedded brain tissue slides in forensics. Int J Legal Med 132:1103–1109. https://doi.org/10.1007/s00414-017-1767-3
26. Remmele W, Steger HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Patholgie 8:138–140
27. Guseł’nikova VV, Korzhuevskiy DE (2015) NeuN as a neuronal nuclear antigen and neuron differentiation marker. Acta Naturae 7:42–47
28. Hol EM, Roelofs RF, Moraal E et al (2003) Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms. Mol Psychiatry 8:786–796. https://doi.org/10.1038/sj.mp.4001379
29. Ottis P, Koppe K, Onisko B et al (2012) Human and rat brain lipofuscin proteome. Proteomics 12:2445–2454. https://doi.org/10.1002/pmic.201100668
30. Double KL, Dedov VN, Fedorow H et al (2008) The comparative biology of neurtelinulin and lipofuscin in the human brain. Cell Mol Life Sci 65:1669–1682. https://doi.org/10.1007/s00018-008-7581-9
31. Goyal VK (1982) Lipofuscin pigment accumulation in human brain during aging. Exp Gerontol 17:481–487. https://doi.org/10.1016/0531-5565(82)80010-7
32. Johnson VE, Stewart W, Arena JD, Smith DH (2017) Traumatic brain injury as a trigger of neurodegeneration. Adv Neurobiol 15:383–400. https://doi.org/10.1007/978-3-319-57193-5_15
33. Clausen T, Khalidi A, Zauner A et al (2005) Cerebral acid-base homeostasis after severe traumatic brain injury. J Neurosurg 103:597–607. https://doi.org/10.1093/jns/2005.103.4.5997
34. Olsson B, Zetterberg H, Hampel H, Blennow K (2011) Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol 95:520–534. https://doi.org/10.1016/j.pneurobio.2011.04.006
35. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7–35. https://doi.org/10.1007/s00401-009-0619-8
36. Emirandetti A, GracieleZanon R, Sabha M Jr, de Oliveira AL (2006) Astrocyte reactivity influences the number of presynaptic terminals apsed to spinal motoneurons after axotomy. Brain Res 1095:35–42. https://doi.org/10.1016/j.brainres.2006.04.021
37. Gimenez YRMA, Langa F, Menet V, Privat A (2000) Comparative anatomy of the cerebellar cortex in mice lacking vimentin, GFAP, and both vimentin and GFAP. Glia 31:69–83. https://doi.org/10.1002/(sici)1098-1136(200007)1:1<0.3c;2-a
38. Lidtke W, Edelmann W, Bieri PL et al (1996) GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17:607–615. https://doi.org/10.1016/0896-6273(96)00194-4
39. McCall MA, Gregg RG, Behringer RR et al (1996) Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl AcadSci U S A 93:6361–6366. https://doi.org/10.1073/pnas.93.13.6361
40. Pekny M, Leveen P, Pekna M et al (1995) Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. EMBO J 14:1590–1598
41. Bender BL, Yunis EJ (1980) Central nervous system pathology of tuberous sclerosis in children. Ultrastruct Pathol 1:287–299. https://doi.org/10.3109/01913128009141432
42. Mullen RJ, Buck CR, Smith AM (1992) NeuN, a neuronal specific nuclear protein in vertebrates. Development 116:201–211
43. Götz M, Hartfuss E, Malatesta P (2002) Radial glial cells as neuronal precursors: a new perspective on the correlation of morphology and lineage restriction in the developing cerebral cortex of mice. Brain Res Bull 57:777–788. https://doi.org/10.1016/s0361-9230(01)00777-8
44. Hartfuss E, Galli R, Heins N, Gotz M (2001) Characterization of CNS precursor subtypes and radial glia. Dev Biol 229:15–30. https://doi.org/10.1006/dbio.2000.9962
45. Malatesta P, Hartfuss E, Gotz M (2000) Isolation of radial glial cells by fluorescent-activated cell sorting reveals a neuronal lineage. Development 127:5253–5263
46. van den Berge SA, Middeldorp J, Zhang CE et al (2010) Longterm quiescent cells in the aged human subventricular neurogenic system specifically express GFAP-delta. Aging Cell 9:313–326. https://doi.org/10.1111/j.1474-9726.2010.00556.x
47. Middeldorp J, Boer K, Sluijs JA et al (2010) GFAPdelta in radial glia and subventricular zone progenitors in the developing human cortex. Development 137:313–321. https://doi.org/10.1242/dev.041632
48. Tramontin AD, Garcia-Verdugo JM, Lim DA, Alvarez-Buylla A (2003) Postnatal development of radial glia and the ventricular zone (VZ): a continuum of the neural stem cell compartment. Cereb Cortex 13:580–587. https://doi.org/10.1093/cercor/13.6.580
49. Zoltewicz JS, Mondello S, Yang B et al (2013) Biomarkers track damage after graded injury severity in a rat model of penetrating brain injury. J Neurotrauma 30:1161–1169. https://doi.org/10.1089/neu.2012.2762
50. Hernandez ML, Chatlos T, Gorse KM, Lafrenaye AD (2019) Neuronal membrane disruption occurs late following diffuse brain trauma in rats and involves a subpopulation of NeuN negative cortical neurons. Front Neurol 10:1238. https://doi.org/10.3389/fneur.2019.01238
51. Akoglu H (2018) User’s guide to correlation coefficients. Turk J Emerg Med 18:91–93. https://doi.org/10.1016/j.tjem.2018.08.001
52. Chan YH (2003) Biostatistics 104: correlational analysis. Singapore Med J 44:614–619
53. Andreuolo F, Juniur MP, Hol EM et al (2009) GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity. Neuropathology 29:31–39. https://doi.org/10.1111/j.1440-1789.2008.00936.x
54. Blechingberg J, Holm IE, Nielsen KB, Jensen TH, Jorgensen AL, Nielsen AL (2007) Identification and characterization of GFAPkappa, a novel glial fibrillary acidic protein isoform. Glia 55:497–507. https://doi.org/10.1002/glia.20475
55. Zelenikova D, Grima B, Brenner M, Pessac B (1995) A novel glial fibrillary acidic protein mRNA lacking exon 1. Brain Res Mol Brain Res 30:251–258. https://doi.org/10.1016/0169-328x(95)00010-p

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.